TREATMENT OF CYTOMEGALO-VIRUS PNEUMONIA IN HEART-TRANSPLANT RECIPIENTS WITH 9(1,3-DIHYDROXY-2-PROPROXYMETHYL)-GUANINE (DHPG)

  • 1 March 1988
    • journal article
    • research article
    • Vol. 7  (2) , 102-105
Abstract
Cytomegalovirus (CMV) infection is a frequent cause of serious illness in heart transplant patients and may cause life-threatening pneumonia, with a reported mortality of > 50%. We investigated the clinical efficacy of a new antiviral agent, 9(1,3-dihydroxy-2-proproxymethyl)-guanine (DHPG) in the treatment of CMV pneumonia in heart transplant patients. Four of these patients with biopsy-proved CMV pneumonia were treated with DHPG, with resolution of pneumonia and no relapse at a mean follow-up period of 21 weeks. DHPG may be useful in the treatment of CMV pneumonia in heart transplant patients.

This publication has 0 references indexed in Scilit: